Logo

Neurome Announces Partnership With ImClone Systems

Sep 24, 2004

NEW YORK, Sept. 24, (GenomeWeb News) - Neurome announced today that it has entered into a research agreement with ImClone Systems in which Neurome will apply its proprietary technologies and expertise in quantitative neuropathology to assist ImClone Systems in the discovery of preclinical candidate molecules.

           

Financial terms of the agreement were not disclosed.

 

"We believe ImClone Systems' decision to work with Neurome is an important validation of our discovery stage capabilities and proprietary technologies," said Floyd Bloom, chairman and founding CEO of Neurome.

 

In August, Neurome announced that it plans to buy all the assets owned by Digital Gene Technologies, including its gene-expression assays and gene-expression-analysis platform called TOGA (see story on Aug. 11).

 

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.